SEP 09, 2020 12:47 PM PDT

New Achondroplasia Treatment

WRITTEN BY: Nouran Amin

A recent clinical trial study found that an experimental drug, known as vosoritide, can be a potential treatment for achondroplasia (a common type of child dwarfism).

"This drug is like releasing the handbrake on a car, it lets you get up to full speed instead of having to drive with the brakes on,” says MCRI clinical geneticist Professor Ravi Savarirayan.

Achondroplasia results in the over activity of a protein FGFR3 that negatively impacts bone growth. Currently treatments involve surgical interventions in comparison—vosoritide can me potentially be a molecular therapy targeting the origins of the disease without invasiveness.

Professor Savarirayan said, "We know that beyond the cold hard facts and figures around growth rates and bone biology, we have hope that a treatment can improve kids' health outcomes, social functioning and increase access to their environments. Anecdotally, our patients tell us they now are able to do more stuff like climbing trees, jumping rocks and being more independent generally, which is specific to their experiences."

Learn more about Achondroplasia:

https://www.youtube.com/watch?v=gt-SAjuikLM

Findings were published in the medical journal, The Lancet and describes how Vosoritide works by blocking FGFR3 activity and returning bone growth to normal.

Dr. Johnathon Day, the Medical Director of Clinical Science at BioMarin Pharmaceutical Inc. notes, "Vosoritide is the first potential precision pharmacological therapy that addresses the underlying cause of achondroplasia and this randomized, double-blind, placebo-controlled Phase 3 study further adds to the scientific knowledge we've gained over many years from the clinical development program. I'd like to personally thank and congratulate all of the investigators and I am especially grateful to all of the children and their families who have participated in these studies.”

Source: Science Daily

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
JUN 24, 2021
Immunology
Should We Rethink COVID Vaccine Recipes?
JUN 24, 2021
Should We Rethink COVID Vaccine Recipes?
In a study reported in the journal Cell, immunologists provide evidence for an Achilles’ heel in current COVI ...
JUN 28, 2021
Microbiology
Small Clinical Trial Suggests New Edible Cholera Vaccine Is Safe
JUN 28, 2021
Small Clinical Trial Suggests New Edible Cholera Vaccine Is Safe
According to WHO there have been six cholera pandemics since the pathogen emerged from the Ganges river delta sometime i ...
JUL 12, 2021
Drug Discovery & Development
Testosterone Supplements Reduce Heart Attack and Stroke Risk
JUL 12, 2021
Testosterone Supplements Reduce Heart Attack and Stroke Risk
Taking testosterone supplements significantly reduces risk of heart attack and stroke among men with low levels of the h ...
JUL 15, 2021
Cannabis Sciences
Cannabis Terpenes Provide Pain Relief in Mice
JUL 15, 2021
Cannabis Terpenes Provide Pain Relief in Mice
Cannabis terpenes, the part of cannabis plants responsible for its smell and taste, may be able to relieve pain both by ...
AUG 25, 2021
Chemistry & Physics
Self-Assembling Molecules: A Potential "One-Size-Fits-All" Cancer Therapy
AUG 25, 2021
Self-Assembling Molecules: A Potential "One-Size-Fits-All" Cancer Therapy
A new study from the University of Huddersfield shows promising breakthroughs on the use of self-assembling molecules as ...
SEP 14, 2021
Drug Discovery & Development
A novel drug that targets the removal of pathogenic antibodies in myasthenia gravis
SEP 14, 2021
A novel drug that targets the removal of pathogenic antibodies in myasthenia gravis
Myasthenia gravis is a chronic autoimmune disorder characterized by muscle weakness and fatigue. The disorder leads to a ...
Loading Comments...